Metronomic Chemotherapy

Topics in Companion Animal Medicine

Volumn 24, Issue 3, 2009, Pages 137-143

  Mutsaers, Anthony J ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

angiogenesis; chemotherapy; microenvironment; oncology; targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DRUG ADMINISTRATION; SARCOMA; SOFT TISSUE TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 69249248116     PISSN: 19389736     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.tcam.2009.03.004     Document Type: Article

References (56)

1. Hanahan D.J., Bergers G., and Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105 (2000) 1045-1047
2. Kamen B.A. Metronomic therapy: it makes sense and is patient friendly. J Pediatr Hematol Oncol 27 (2005) 571-572
3. Skipper H.E., Schabel F.M., and Mellet L.B. Implications of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 54 (1970) 431-450
4. Kamen B.A., Glod J., and Cole P.D. Metronomic therapy from a pharmacologist's view. J Pediatr Hematol Oncol 28 (2006) 325-327
5. Kamen B.A., Rubin E., Glatstein E., et al. High time chemotherapy or high time for low dose. J Clin Oncol 18 (2000) 2935-2937
6. Kerbel R.S., and Kamen B.A. Antiangiogenic basis of low-dose metronomic chemotherapy. Nature Rev Cancer 4 (2004) 423-436
7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
8. Miller K.D., Sweeney C.J., and Sledge G.W. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19 (2001) 1195-1206
9. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
10. Klement G., Baruchel S., Rak J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105 (2000) R15-R24
11. Emmenegger U., Man S., Shaked Y., et al. A comparative analysis of low dose metronomic cyclophosphamide reveals absent or low grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 64 (2004) 3994-4000
12. Bocci G., Nicolaou K.C., and Kerbel R. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62 (2002) 6938-6943
13. Wang J., Lou R., Lesniewski R., et al. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14 (2003) 13-19
14. Vacca A., Iurlaro M., Ribatti D., et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94 (1999) 4143-4155
15. Kerbel R.S. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell 8 (2005) 269-271
16. Rak J., Yu J.L., Kerbel R.S., et al. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?. Cancer Res 62 (2002) 1931-1934
17. Bocci G., Francia G., Man S., et al. Thombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 100 (2003) 12917-12922
18. Hamano Y., Sugimoto H., Soubasakos M.A., et al. Thombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64 (2004) 1570-1574
19. Kieran M.W., Turner C.D., Rubin J.B., et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27 (2005) 573-581
20. Yap R., Veliceasa D., Emmenegger U., et al. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 11 (2005) 6678-6685
21. Damber J.E., Vallbo C., Albertsson P., et al. The anti-tumor effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 58 (2006) 354-360
22. Rusk A., McKeegan E., Haviv F., et al. Preclinical evaluation of anti-angiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 12 (2006) 7444-7455
23. Rusk A., Cozzi E., Stebbins M., et al. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-1 peptides, ABT-526 in pet dogs with relapsed lymphoma. Clin Cancer Res 12 (2006) 7456-7464
24. Asahara T., Murahara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
25. Bertolini F., Paul S., Mancuso P., et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63 (2003) 4342-4346
26. Bergman P.J. Anticancer vaccines. Vet Clin North Am Small Anim Pract 37 (2007) 1111-1119
27. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56 (2007) 641-648
28. Biller B.J., Elmslie R.E., Burnett R.C., et al. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet Immunol Immunopathol 116 (2007) 69-78
29. Walter C.U., Biller B.J., Lana S.E., et al. Effects of chemotherapy on immune responses in dogs with cancer. J Vet Intern Med 20 (2006) 342-347
30. Garrett L.D., Thamm D.H., Chun R., et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 16 (2002) 704-709
31. Ogilvie G.K., Vail D.M., Klein M.K., et al. Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs. J Amer Vet Med Assoc 198 10 (1991) 1762-1764
32. Hahn K.A., Rohrbach B.W., Legendre A.M., et al. Hematologic changes associated with weekly low-dose cisplatin administration in dogs. Vet Clin Pathol 26 (1997) 29-31
33. Colleoni M., Rocca A., Sandri M.T., et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13 (2002) 73-80
34. Orlando L., Cardillo A., Rocca A., et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 17 (2006) 961-967
35. Buckstein R., Crump M., Shaked Y., et al. High dose celecoxib and metronomic "low dose" cyclophosphamide is effective and safe therapy in patients with relapsed and refractory aggressive histology NHL. Clin Cancer Res 12 (2006) 5190-5198
36. Vogt T., Hafner C., Bross K., et al. Antiangiogenic therapy with pioglitazone, rofecoxib, and metronomic trofosphamide in patients with advanced malignant vascular tumors. Cancer 98 (2003) 2251-2256
37. Kopp H.G., Kanz L., and Hartmann J.T. Complete remission of relapsing high-grade angiosarcoma with single-agent metronomic trophosphamide. Anticancer Drugs 17 (2006) 997-998
38. Reichle A., Bross K., Vogt T., et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosphamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 101 (2004) 2247-2256
39. Lord R., Nair S., Schache A., et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 177 (2007) 2136-2140
40. Glode L.M., Crighton F., Barqawi A., et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate cancer. Cancer 98 (2003) 1643-1648
41. Kong D.S., Lee J.I., Kim W.S., et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16 (2006) 1117-1121
42. Correale P., Cerretani D., Remondo C., et al. A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 16 (2006) 133-140
43. Krzyzanowska M.K., Tannock I.F., Lockwood G., et al. A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother Pharmacol 60 (2007) 135-141
44. Mutsaers, AJ, Mohammed, SI, DeNicola, DB, et al: "Metronomic" chemotherapy in veterinary oncology, a pilot study [abstract]. Proceedings of the 21st Veterinary Cancer Society Conference. Baton Rouge, LA, 2001
45. Mutsaers A.J. Chemotherapy: new uses for old drugs. Vet Clin North Am Small Anim Pract 37 (2007) 1079-1090
46. Lana S., U'Ren L., Plaza S., et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med 21 (2007) 764-769
47. Elmslie R.E., Glawe P., and Dow S.W. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med 22 (2008) 1373-1379
48. Charney S.C., Bergman P.J., Hohenhaus A.E., et al. Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990-1996). J Am Vet Med Assoc 222 (2003) 1388-1393
49. Kato H., Ichinose Y., Ohta M., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004) 1713-1721
50. Paoloni M., and Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8 (2008) 147-156
51. Shaked Y., Emmenegger U., Francia G., et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 65 (2005) 7045-7051
52. Tran J., Master Z., Yu J.L., et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 99 (2002) 4349-4354
53. Garcia A.A., Hirte H., Fleming G., et al. Phase II clinical trial of bevacizumab and low- dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26 (2008) 76-82
54. Petit A.M., Rak J., and Hung M.C. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151 (1997) 1523-1530
55. London C.A., Hannah A.L., Zadovoskaya R., et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 9 (2003) 2755-2768
56. Hahn K.A., Ogilvie G., Rusk T., et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 22 (2008) 1301-1309